Interferon-alpha (IFN-α) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway

被引:0
|
作者
Kaser, A [1 ]
Enrich, B [1 ]
Ludwiczek, O [1 ]
Vogel, W [1 ]
Tilg, H [1 ]
机构
[1] Univ Innsbruck Hosp, Dept Med, Div Gastroenterol & Hepatol, A-6020 Innsbruck, Austria
来源
CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 1999年 / 118卷 / 01期
关键词
interferon-alpha; hepatitis C infection; cytotoxicity; perforin; Fas ligand;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cell-mediated cytotoxicity is exerted via perforin and Fas ligand (FasL). We have recently shown that IFN-alpha up-regulates Fast expression in T cells isolated from healthy volunteers and augments activation-induced T cell death. Since the Fas/FasL system is implicated in the pathogenesis of hepatic failure and both molecules have been shown to be up-regulated in hepatitis C virus (HCV) infection, we studied whether cytotoxicity via the Fast system is enhanced by IFN-alpha and therefore could contribute to hepatic injury. We investigated Fast and perforin expression in peripheral blood mononuclear cells (PBMC) derived from HCV+ donors by Northern analysis and soluble Fast synthesis by ELISA. Natural killer (NK) cell and cytotoxic T lymphocyte (CTL) cytotoxicity was studied by Cr-51-release assays. IFN-alpha up-regulates Fast mRNA and protein synthesis in mitogen-activated PBMC of HCV+ individuals, as previously found in healthy subjects. Stimulation with IFN-alpha increases perforin mRNA levels in PBMC. In NK cytotoxicity assays, the enhancement of cytotoxicity by IFN-alpha is mainly due to the perforin pathway, while the Fast pathway plays only a minor role. In CTL cytotoxicity experiments neither the Fast nor the perforin pathway is further enhanced by IFN-alpha. Our data suggest that upregulation of perforin by IFN-alpha results in elevated cytotoxicity, suggesting that IFN-alpha might support elimination of virally infected cells via this pathway. In contrast, the major effect of IFN-alpha on the Fas/FasL system might be the enhanced elimination of activated T cells as a means of finally limiting a T cell response.
引用
收藏
页码:71 / 77
页数:7
相关论文
共 50 条
  • [41] PREDICTIVE FACTORS OF RESPONSE TO INTERFERON-ALPHA (IFN) IN CHRONIC HEPATITIS-C - WHAT FACTORS FOR WHAT RESPONSE
    PAWLOTSKY, JM
    ROUDOTTHORAVAL, F
    BASTIE, A
    PELLET, C
    BABANY, G
    DUVAL, J
    DHUMEAUX, D
    HEPATOLOGY, 1995, 22 (04) : 272 - 272
  • [42] Does the interferon-lambda rather than the interferon-alpha pathway determine the outcome of hepatitis C virus infection?
    Mihm, Sabine
    Spengler, U.
    Amanzada, Ahmad
    Ramadori, Giuliano
    HEPATOLOGY, 2014, 60 (04) : 1437 - 1439
  • [43] Syndrome of chronic fatigue in patients receiving interferon-alpha for chronic hepatitis C
    Raison, CL
    Borisov, AS
    Broadwell, SD
    Capuron, L
    Woolwine, BJ
    Nemeroff, CB
    Miller, AH
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S234 - S235
  • [44] CHRONIC HEPATITIS-C AND INTERFERON-ALPHA (IFN-ALPHA) - MANAGEMENT OF PATIENTS WHO RELAPSE OR DO NOT RESPOND TO TREATMENT
    HOSSLI, SM
    BAKER, AL
    HEPATOLOGY, 1995, 22 (04) : 1296 - 1296
  • [45] Chronic hepatitis C - What treatment for nonresponders to recombinant interferon-alpha?
    Bresci, G
    Parisi, G
    Banti, S
    Scatena, F
    Bertoni, M
    Capria, A
    CLINICAL DRUG INVESTIGATION, 1996, 11 (04) : 224 - 228
  • [46] Interferon-alpha (IFN-α) alters haemopoietic progenitor cell kinetics in chronic myeloid leukaemia (CML)
    Marley, SB
    Davidson, RJ
    Grand, FH
    Goldman, JM
    Gordon, MY
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 182 - 182
  • [47] mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)-infected patients:: effects of interferon-alpha (IFN-α) treatment
    Shapiro, S
    Gershtein, V
    Eliast, N
    Zuckerman, E
    Salman, N
    Lahat, N
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1998, 114 (01): : 55 - 60
  • [48] Subacute thyroiditis during interferon-alpha therapy for chronic hepatitis C
    Paolo Falaschi
    A. Martocchia
    R. D’Urso
    A. Proietti
    Journal of Endocrinological Investigation, 1997, 20 : 24 - 28
  • [49] TREATMENT OF CHRONIC HEPATITIS-C WITH WEEKLY ADMINISTRATION OF INTERFERON-ALPHA
    MORIZANE, T
    KAGAWA, T
    SAITO, H
    GUEVARA, FM
    MIYAGUCHI, S
    TSUCHIYA, M
    GASTROENTEROLOGIA JAPONICA, 1991, 26 : 254 - 255
  • [50] Interferon-alpha therapy for chronic hepatitis C in special patient populations
    Marcellin, P
    Boyer, N
    Behamou, JP
    Erlinger, S
    DIGESTIVE DISEASES AND SCIENCES, 1996, 41 (12) : S126 - S130